Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS
Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
TP53 mutation is commonly associated with poor cancer patient prognosis yet no mutant p53
(mp53)-targeting regimen was clinically established. Here the investigators try to evaluate
the side effect and treatment potential of DAC+ATO in p53 mutated high-risk AML/MDS patients.
About 200 AML/MDS patients will be sequenced for TP53 sequence before recruitment. The
investigators estimated about 5 patients, based on the reported p53 mutation frequency in
AML/MDS, will be p53-mutated. In the trial, the investigators will selectively recruit the
mp53 AML/MDS patients that are predicted to respond to DAC+ATO regimen with highest chance
(based on the relevant basic studies).
The investigators designate mutant p53-based clinical trials as 'PANDA (P53 AND
Arsenic)-Trials'.